RIVAROXABAN
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Direct Factor Xa inhibitor; selectively and reversibly inhibits free and clot-bound Factor Xa, thereby inhibiting thrombin generation and thrombus formation.
| Metabolism | Primarily metabolized via CYP3A4/5 and CYP2J2; also undergoes hydrolysis (non-CYP). Approximately 66% of the dose undergoes hepatic metabolism; renal excretion accounts for 33% of the dose (36% as unchanged drug, 30% as metabolites). |
| Excretion | Renal: 33% as unchanged drug, 33% as inactive metabolites (via CYP3A4/5, CYP2J2, and amidase hydrolysis). Fecal: 33% as unchanged drug and metabolites (via biliary and direct intestinal secretion). |
| Half-life | Terminal elimination half-life: 5-9 hours in young adults, 11-13 hours in elderly. Clinical context: Prolonged in renal impairment (CrCl 15-29 mL/min: half-life ~8.8 h; CrCl <15 mL/min: not studied); direct oral anticoagulant with once or twice daily dosing based on indication. |
| Protein binding | 92-95% bound to albumin (serum albumin >5 g/L). |
| Volume of Distribution | Approximately 50 L (0.5-0.8 L/kg) in adults. Clinical meaning: Moderate distribution, primarily in intravascular space and well-perfused tissues; low tissue penetration. |
| Bioavailability | Oral: 80-100% under fasting conditions; 100% with food (increases Cmax by 39% and AUC by 76%). No intravenous formulation. |
| Onset of Action | Oral: Peak anticoagulant effect (anti-FXa activity) within 2-4 hours; inhibition of thrombin generation measurable within 1-2 hours. |
| Duration of Action | Anticoagulant effect persists for at least 12-24 hours after single dose. Clinical note: Dosing frequency is once or twice daily based on risk (e.g., once daily for atrial fibrillation, twice daily for acute VTE). Carry-over effect minimal due to half-life. |
For atrial fibrillation: 20 mg orally once daily with food. For VTE treatment: 15 mg orally twice daily with food for 21 days, then 20 mg once daily. For VTE prophylaxis after hip/knee replacement: 10 mg orally once daily for 35 days (hip) or 12 days (knee). For ACS: 2.5 mg orally twice daily plus aspirin.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-49 mL/min: 15 mg once daily for AF (if CrCl 15-49 mL/min). For VTE treatment, reduce to 15 mg once daily after initial 21 days if CrCl 30-49 mL/min. CrCl 15-29 mL/min: 15 mg once daily for AF; avoid for VTE treatment unless urgent. CrCl <15 mL/min: avoid use. For VTE prophylaxis, no adjustment needed if CrCl ≥30 mL/min; avoid if CrCl <30 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: avoid use due to significant increase in exposure. Child-Pugh C: contraindicated. Avoid in any patient with hepatic disease associated with coagulopathy. |
| Pediatric use | For VTE treatment: weight-based dosing. ≥50 kg: 20 mg once daily. 30-49 kg: 15 mg once daily. <30 kg: not recommended (limited data). Use oral suspension if available. For prophylaxis, not indicated in pediatric patients. |
| Geriatric use | No specific dose adjustment based on age alone. Monitor renal function closely. For AF, if CrCl ≥50 mL/min, use 20 mg daily; if CrCl 15-49 mL/min, use 15 mg daily. Consider overall bleeding risk: elderly patients at increased risk, especially those ≥80 years old, low body weight, or with renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Strong dual inducers of CYP3A4 and P-gp decrease levels increasing stroke risk Risk of serious and fatal bleeding discontinue if active bleeding occurs.
| Breastfeeding | Excreted in human milk. M/P ratio approximately 0.13. Due to potential for serious adverse reactions (bleeding) in nursing infants, advise women not to breastfeed while taking rivaroxaban. |
| Teratogenic Risk | Pregnancy category X. Avoid in all trimesters. First trimester: increased risk of spontaneous abortion and fetal hemorrhage. Second/third trimesters: risk of fetal bleeding, placental abruption, and preterm labor due to anticoagulant effect. Contraindicated in pregnancy. |
■ FDA Black Box Warning
Premature discontinuation of rivaroxaban increases the risk of thrombotic events. Epidural or spinal hematomas may occur in patients receiving neuraxial anesthesia or spinal puncture, leading to long-term or permanent paralysis.
| Common Effects | VTE treatment |
| Serious Effects |
["Active pathological bleeding","Severe hypersensitivity to rivaroxaban","Concomitant treatment with other anticoagulants (except during switching or when given for specific procedures)","Patients with mechanical prosthetic heart valves","Pregnancy (not recommended; Caution in breastfeeding)"]
| Precautions | ["Increased risk of thrombotic events if discontinued prematurely","Risk of epidural/spinal hematoma with neuraxial procedures","Increased risk of bleeding, including intracranial hemorrhage","Not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B and C) or hepatic coagulopathy","Use with caution in renal impairment (CrCl <30 mL/min is not recommended)","Monitor for signs of bleeding and anemia","Avoid use with strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, ritonavir, conivaptan)"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal signs of bleeding (e.g., bruising, epistaxis, GI bleeding). Assess fetal growth and amniotic fluid index by ultrasound if inadvertent exposure. Monitor for placental abruption. Avoid neuraxial anesthesia due to spinal hematoma risk. |
| Fertility Effects | No human data on fertility effects. In animal studies, no impairment of fertility observed at exposures up to 4 times human exposure. Theoretical risk of ovarian hemorrhage with ovulation induction. |